Omnicell, Inc. (NASDAQ:OMCL) Receives $52.33 Consensus PT from Brokerages

Omnicell, Inc. (NASDAQ:OMCL) has received an average rating of “Hold” from the six analysts that are currently covering the firm, Marketbeat reports. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $52.33.

Several research analysts have recently weighed in on the stock. JPMorgan Chase & Co. increased their price objective on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Wells Fargo & Company cut their price target on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Benchmark restated a “buy” rating and issued a $62.00 price target on shares of Omnicell in a report on Tuesday, February 4th. Bank of America lowered their price objective on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research report on Monday, January 6th. Finally, StockNews.com raised shares of Omnicell from a “hold” rating to a “buy” rating in a research report on Thursday, March 6th.

Institutional Trading of Omnicell

A number of hedge funds have recently made changes to their positions in OMCL. Apollon Wealth Management LLC acquired a new stake in shares of Omnicell during the third quarter worth approximately $249,000. Sumitomo Mitsui Trust Group Inc. acquired a new stake in shares of Omnicell during the third quarter worth approximately $32,721,000. Victory Capital Management Inc. grew its position in shares of Omnicell by 11,982.3% during the third quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company’s stock worth $50,071,000 after buying an additional 1,138,921 shares in the last quarter. Curi RMB Capital LLC grew its position in shares of Omnicell by 0.7% during the third quarter. Curi RMB Capital LLC now owns 88,815 shares of the company’s stock worth $3,872,000 after buying an additional 651 shares in the last quarter. Finally, Royce & Associates LP acquired a new stake in shares of Omnicell during the third quarter worth approximately $811,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Price Performance

NASDAQ:OMCL opened at $33.00 on Friday. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of 122.23, a price-to-earnings-growth ratio of 7.53 and a beta of 0.85. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. The company’s 50-day moving average is $40.71 and its two-hundred day moving average is $43.27. Omnicell has a 12-month low of $25.12 and a 12-month high of $55.75.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. Research analysts expect that Omnicell will post 1.09 EPS for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.